X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs LUPIN LTD - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA LUPIN LTD CIPLA/
LUPIN LTD
 
P/E (TTM) x 38.2 163.6 23.3% View Chart
P/BV x 3.9 3.0 129.1% View Chart
Dividend Yield % 0.3 0.8 39.7%  

Financials

 CIPLA   LUPIN LTD
EQUITY SHARE DATA
    CIPLA
Mar-17
LUPIN LTD
Mar-17
CIPLA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs6221,750 35.5%   
Low Rs4581,384 33.1%   
Sales per share (Unadj.) Rs181.9387.4 46.9%  
Earnings per share (Unadj.) Rs12.956.6 22.7%  
Cash flow per share (Unadj.) Rs29.376.8 38.2%  
Dividends per share (Unadj.) Rs2.007.50 26.7%  
Dividend yield (eoy) %0.40.5 77.4%  
Book value per share (Unadj.) Rs155.7298.9 52.1%  
Shares outstanding (eoy) m804.51451.58 178.2%   
Bonus/Rights/Conversions ESOPESOPS-  
Price / Sales ratio x3.04.0 73.4%   
Avg P/E ratio x42.027.7 151.7%  
P/CF ratio (eoy) x18.420.4 90.4%  
Price / Book Value ratio x3.55.2 66.2%  
Dividend payout %15.513.2 117.3%   
Avg Mkt Cap Rs m434,516707,513 61.4%   
No. of employees `00023.016.8 137.2%   
Total wages/salary Rs m26,33828,495 92.4%   
Avg. sales/employee Rs Th6,349.110,418.3 60.9%   
Avg. wages/employee Rs Th1,143.01,697.0 67.4%   
Avg. net profit/employee Rs Th449.31,523.0 29.5%   
INCOME DATA
Net Sales Rs m146,302174,943 83.6%  
Other income Rs m2,2871,065 214.7%   
Total revenues Rs m148,589176,008 84.4%   
Gross profit Rs m24,75844,931 55.1%  
Depreciation Rs m13,2299,122 145.0%   
Interest Rs m1,5941,525 104.5%   
Profit before tax Rs m12,22235,349 34.6%   
Minority Interest Rs m0-72 0.0%   
Prior Period Items Rs m-7083 -84.7%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,7989,785 18.4%   
Profit after tax Rs m10,35425,575 40.5%  
Gross profit margin %16.925.7 65.9%  
Effective tax rate %14.727.7 53.1%   
Net profit margin %7.114.6 48.4%  
BALANCE SHEET DATA
Current assets Rs m87,370119,542 73.1%   
Current liabilities Rs m33,08161,206 54.0%   
Net working cap to sales %37.133.3 111.3%  
Current ratio x2.62.0 135.2%  
Inventory Days Days8776 114.4%  
Debtors Days Days6290 69.3%  
Net fixed assets Rs m111,567131,660 84.7%   
Share capital Rs m1,609903 178.1%   
"Free" reserves Rs m123,645134,073 92.2%   
Net worth Rs m125,254134,976 92.8%   
Long term debt Rs m36,45456,478 64.5%   
Total assets Rs m209,532266,073 78.7%  
Interest coverage x8.724.2 35.9%   
Debt to equity ratio x0.30.4 69.6%  
Sales to assets ratio x0.70.7 106.2%   
Return on assets %5.710.2 56.0%  
Return on equity %8.318.9 43.6%  
Return on capital %8.519.3 44.1%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06681,885 62.4%   
Fx outflow Rs m17,67821,506 82.2%   
Net fx Rs m33,38860,378 55.3%   
CASH FLOW
From Operations Rs m23,82441,148 57.9%  
From Investments Rs m-13,127-25,287 51.9%  
From Financial Activity Rs m-13,2394,332 -305.6%  
Net Cashflow Rs m-2,47820,193 -12.3%  

Share Holding

Indian Promoters % 16.0 46.6 34.3%  
Foreign collaborators % 20.8 0.2 10,400.0%  
Indian inst/Mut Fund % 12.2 11.3 108.0%  
FIIs % 23.7 31.9 74.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.1 259.4%  
Shareholders   161,166 98,259 164.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   J.B.CHEMICALS  SUVEN LIFE  STERLING BIOTECH  CADILA HEALTHCARE  VENUS REMEDIES  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8%

May 24, 2018 | Updated on May 24, 2018

For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jun 15, 2018 (Close)

TRACK CIPLA

CIPLA - BIOCON LTD COMPARISON

COMPARE CIPLA WITH

MARKET STATS